House Republicans Challenge FDA On Warning Letter Appeals Process
This article was originally published in The Tan Sheet
Executive Summary
Senior Republicans on the House Energy & Commerce Committee are challenging FDA on the fairness of its warning letter appeals process, questioning whether the agency "really provides a good-faith option of appeal.
You may also be interested in...
House Republicans Seek Top Down Change To FDA’s Warning-Letter Appeals
FDA leadership needs to review the agency's enforcement dispute resolution process, according to ranking Republicans on the House Energy and Commerce Committee
Pharmachem Gains Phase 2 Claims Agreement, Plus Patent For New Product
Pharmachem Laboratories' experience with claims for its Phase 2 starch-neutralizer branded ingredient may provide an example for firms seeking to validate claims with the FDA, the firm says
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.